Sarepta Therapeutics (SRPT) Competitors $54.63 +3.60 (+7.05%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SRPT vs. TEVA, ITCI, SMMT, GMAB, RDY, MRNA, VTRS, QGEN, ASND, and ROIVShould you be buying Sarepta Therapeutics stock or one of its competitors? The main competitors of Sarepta Therapeutics include Teva Pharmaceutical Industries (TEVA), Intra-Cellular Therapies (ITCI), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Viatris (VTRS), Qiagen (QGEN), Ascendis Pharma A/S (ASND), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry. Sarepta Therapeutics vs. Teva Pharmaceutical Industries Intra-Cellular Therapies Summit Therapeutics Genmab A/S Dr. Reddy's Laboratories Moderna Viatris Qiagen Ascendis Pharma A/S Roivant Sciences Sarepta Therapeutics (NASDAQ:SRPT) and Teva Pharmaceutical Industries (NYSE:TEVA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, community ranking, dividends, analyst recommendations and institutional ownership. Is SRPT or TEVA more profitable? Sarepta Therapeutics has a net margin of 7.43% compared to Teva Pharmaceutical Industries' net margin of -9.91%. Teva Pharmaceutical Industries' return on equity of 42.46% beat Sarepta Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Sarepta Therapeutics7.43% 11.00% 3.35% Teva Pharmaceutical Industries -9.91%42.46%6.65% Do insiders and institutionals hold more shares of SRPT or TEVA? 86.7% of Sarepta Therapeutics shares are held by institutional investors. Comparatively, 54.0% of Teva Pharmaceutical Industries shares are held by institutional investors. 7.7% of Sarepta Therapeutics shares are held by insiders. Comparatively, 0.6% of Teva Pharmaceutical Industries shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community believe in SRPT or TEVA? Sarepta Therapeutics received 137 more outperform votes than Teva Pharmaceutical Industries when rated by MarketBeat users. Likewise, 75.05% of users gave Sarepta Therapeutics an outperform vote while only 67.85% of users gave Teva Pharmaceutical Industries an outperform vote. CompanyUnderperformOutperformSarepta TherapeuticsOutperform Votes147175.05% Underperform Votes48924.95% Teva Pharmaceutical IndustriesOutperform Votes133467.85% Underperform Votes63232.15% Which has stronger earnings & valuation, SRPT or TEVA? Sarepta Therapeutics has higher earnings, but lower revenue than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSarepta Therapeutics$1.90B2.69-$535.98M$2.2823.13Teva Pharmaceutical Industries$16.54B0.93-$1.64B-$1.45-9.32 Does the media prefer SRPT or TEVA? In the previous week, Sarepta Therapeutics had 22 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 45 mentions for Sarepta Therapeutics and 23 mentions for Teva Pharmaceutical Industries. Teva Pharmaceutical Industries' average media sentiment score of 1.10 beat Sarepta Therapeutics' score of 0.38 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sarepta Therapeutics 14 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 6 Negative mention(s) 4 Very Negative mention(s) Neutral Teva Pharmaceutical Industries 16 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend SRPT or TEVA? Sarepta Therapeutics currently has a consensus target price of $161.83, indicating a potential upside of 206.90%. Teva Pharmaceutical Industries has a consensus target price of $23.43, indicating a potential upside of 73.29%. Given Sarepta Therapeutics' higher probable upside, equities research analysts clearly believe Sarepta Therapeutics is more favorable than Teva Pharmaceutical Industries.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sarepta Therapeutics 0 Sell rating(s) 5 Hold rating(s) 18 Buy rating(s) 1 Strong Buy rating(s) 2.83Teva Pharmaceutical Industries 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 Which has more volatility and risk, SRPT or TEVA? Sarepta Therapeutics has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500. Comparatively, Teva Pharmaceutical Industries has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500. SummarySarepta Therapeutics beats Teva Pharmaceutical Industries on 14 of the 19 factors compared between the two stocks. Remove Ads Get Sarepta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SRPT vs. The Competition Export to ExcelMetricSarepta TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.12B$6.33B$5.32B$7.55BDividend YieldN/A3.20%5.11%4.34%P/E Ratio42.186.7521.6217.70Price / Sales2.69225.79373.9693.31Price / CashN/A65.6738.1534.64Price / Book5.745.806.383.95Net Income-$535.98M$141.32M$3.20B$247.24M7 Day Performance0.63%3.68%5.15%5.01%1 Month Performance-45.75%-14.02%-7.51%-6.50%1 Year Performance-57.08%-15.82%7.35%-2.61% Sarepta Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SRPTSarepta Therapeutics4.682 of 5 stars$54.63+7.1%$161.83+196.2%-58.5%$5.30B$1.90B43.70840Analyst ForecastShort Interest ↑Gap DownTEVATeva Pharmaceutical Industries2.9882 of 5 stars$13.89+0.7%$23.43+68.6%+0.9%$15.81B$16.54B-9.6236,800Options VolumePositive NewsITCIIntra-Cellular Therapies3.4982 of 5 stars$131.87flat$106.23-19.4%N/A$14.05B$680.50M-151.57560Analyst ForecastPositive NewsSMMTSummit Therapeutics2.6154 of 5 stars$17.28-0.5%$35.40+104.8%+534.1%$12.81B$700,000.00-62.00110Gap UpGMABGenmab A/S4.2241 of 5 stars$18.25-0.8%$41.33+126.5%-35.7%$12.08B$21.53B10.491,660Short Interest ↓Gap DownHigh Trading VolumeRDYDr. Reddy's Laboratories3.0786 of 5 stars$12.58+1.7%$17.00+35.2%-7.5%$10.51B$311.31B20.0624,800Positive NewsHigh Trading VolumeMRNAModerna4.2556 of 5 stars$25.30+0.8%$59.00+133.2%-75.1%$9.79B$3.20B-2.733,900Positive NewsGap UpVTRSViatris2.7984 of 5 stars$7.63+0.1%$10.50+37.7%-33.5%$9.10B$14.74B-10.3037,000QGENQiagen3.496 of 5 stars$40.21+5.1%$47.71+18.6%+7.5%$8.96B$1.98B112.236,030High Trading VolumeASNDAscendis Pharma A/S2.2866 of 5 stars$138.62-2.8%$204.64+47.6%+3.4%$8.44B$363.64M-19.591,017News CoveragePositive NewsGap DownROIVRoivant Sciences2.5826 of 5 stars$9.24-2.4%$17.50+89.5%-9.9%$6.60B$122.59M-61.70860Positive NewsGap DownHigh Trading Volume Remove Ads Related Companies and Tools Related Companies Teva Pharmaceutical Industries Competitors Intra-Cellular Therapies Competitors Summit Therapeutics Competitors Genmab A/S Competitors Dr. Reddy's Laboratories Competitors Moderna Competitors Viatris Competitors Qiagen Competitors Ascendis Pharma A/S Competitors Roivant Sciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SRPT) was last updated on 4/14/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredTrump’s betrayal exposed Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | SponsoredIf Gold Is ‘Stalling,’ Why Are Banks Hoarding Billions In Secret?Prosperity was something every American family could build, protect, and pass down. Because that's what legacy...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sarepta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sarepta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SRPT Stock Free SRPT Stock Alerts